Retatrutide
Retatrutide (LY3437943)
Limited humanfat_lossmetabolic
Community score3.50 reviews · 0 tracking
An investigational triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly. Phase 2 data showed up to 24% mean body-weight reduction at 12 mg over 48 weeks. Not yet FDA-approved; phase 3 trials ongoing.
For research and personal log purposes. peptidio does not sell, ship, prescribe, or endorse any peptide for the prevention, treatment, or cure of any condition.